

Australasian Speakers

Mr Morgan Atkinson, SA

Morgan Atkinson is an Exercise Physiologist at the Centre for Physical Activity in Ageing (CPAA) located at the Hampstead Rehabilitation Centre, Hampstead, South Australia. An accredited exercise physiologist, he is Program Coordinator of the Cancer and Exercise Program at the CPAA.

Narin Bak, SA

Narin Bak is a staff specialist physician at The Royal Adelaide Hospital infectious diseases unit. He has been a staff specialist in infectious diseases for the last 10 years. He graduated in medicine from The University of Melbourne and trained at The Royal Melbourne Hospital and The Alfred Hospital in Melbourne. He has a broad clinical interest in infection especially infections in immunocompromised hosts and is a member of the Australian New Zealand Mycosis Interest Group. He obtained his epidemiology and master of public health from The University of Melbourne and Monash University.

Dr Ross Baker, WA

Ross Baker is the Director of the Centre for Thrombosis and Haemophilia (CTH), Murdoch University, Senior Consultant Haematologist, Royal Perth Hospital and Head of the Haemophilia Centre of Western Australia. He has been Past President of the ASTH, HSA NZ Councillor and member of the Haematology discipline advisory committee of RCPA. His special interest is translational research from the bench to bedside in disorders of thrombosis and haemostasis.

Dr Chris Barnes, Henry Eckert Haemophilia Centre, VIC

Dr Marija Borosak, VIC

Transfusion Medicine Specialist at the Australian Red Cross Blood Service (ARCBS) since May 2005. Dr Borosak is a consultant haematologist and is part of the national ARCBS Transfusion Medicine Team (TMS). The multidisciplinary TMS teams provide clinical and scientific advice in order to continually improve the safety, sufficiency and management of the blood supply and clinical transfusion practise. Dr Borosak has experience in intravenous immunoglobulin supply review and approval management and chairs the ARCBS national IVIg working group. She has recently become the ARCBS representative for the IVIg criteria review

process. She serves as the Chair of the patient blood management group and is a member of the Advisory Committee of Blood Matters.

Ms Sharon Bowering, SA

Sharon Bowering is a registered nurse and currently employed as the state - wide cancer care coordinator for adolescents and young adults in South Australia. Her nursing experience is diverse with the last 10 years centered upon paediatric oncology/ haematology, adult and paediatric palliative care. She has a special interest in adolescent palliative care and the role of young people as empowered decision makers in cancer care. She has an academic appointment with the School of Medicine, Flinders University.

Professor Ken Bradstock, Westmead Hospital, NSW

Dr Susan Branford, SA

Susan Branford is a medical scientist in the Division of Molecular Pathology at the Institute of Medical and Veterinary Science and an associate professor of the University of Adelaide School of Medicine in Adelaide, South Australia. Dr Branford received her PhD in biomedical sciences from the University of South Australia. Her research focuses on molecular analysis of patients with chronic myeloid leukemia (CML) treated with kinase inhibitor therapy. These analyses include monitoring the levels of BCR-ABL mRNA as an indication of treatment response, and resistance assessment by mutation analysis of the BCR-ABL kinase domain. She contributes significantly to the formulation of international guidelines for the performance and standardization of the molecular methods used internationally. In addition, she is participating in a project to standardize BCR-ABL values to an international reporting scale.

Dr Peter Browett, University of Auckland, NZ

Dr Kate Burbury, VIC

Kate Burbury completed her medical training at the University of Tasmania and was awarded a Rhodes Scholarship in 1994, which enabled her to complete a DPhil at Oxford University in Clinical Epidemiology. Since completing her advanced training in Haematology (Joint Training Scheme), she has been working at Peter MacCallum Cancer Centre. Major interest is in the intricate relationship between haemostasis and cancer.

Mr Ken Davis, SA

Ken Davis is Chief Medical Scientist in the Transfusion Medicine Unit, SA Pathology at the Royal Adelaide Hospital. He chairs the Clinical User Group committee, ARCBS, Adelaide and is a member of the South Australian Blood Sector Advisory Committee [SABSAC] and the SA 'BloodSafe' steering committee. He has served two six year terms [2001 - 2007] on the Council of the Australian and New Zealand Society of Blood Transfusion [ANZSBT], holding the office of President from 2003 to 2007. His major interests are in the appropriate use of blood products, blood safety and quality especially at the user interface [patient safety] and education in laboratory and clinical transfusion practice.

Ms Julie Domanski, NT

Julie Domanski is the Transfusion Nurse for the Northern Territory Hospital Network. She has been in this role since early 2008 and is currently based at the Royal Darwin Hospital. Julie has previously worked for the ARCBS in donor collection and apheresis, and for the Peter MacCallum Cancer Centre in the therapeutic apheresis unit. She served as the Transfusion Nurse at Southern Health in Victoria as part of the Blood Matters collaborative from 2003 to 2008, and was a member of the Expert Group for the Serious Transfusion Incident Reporting Program.

Dr Elizabeth Duncan, SA

Elizabeth Duncan is the Senior Medical Scientist responsible for the Special Haemostasis Laboratory at the Institute of Medical and Veterinary Science. Her role mainly comprises responsibility for specialised haemostasis investigations. This continually offers many challenges in diagnosis, test development and research. Her particular interest is the study of bleeding disorders and in recent years this has broadened to include laboratory diagnosis of rare disorders including FXIII deficiency.

Dr John Eikelboom, Canada

John Eikelboom, MBBS is Associate Professor, Department of Medicine, McMaster University, and Haematologist, Thrombosis Service, Hamilton General Hospital. He completed training in Internal Medicine and Haematology in Perth, Australia in 1998 and subsequently undertook a fellowship in Thrombosis Medicine and Clinical Epidemiology at

McMaster University. He returned to McMaster in 2005 to take up a Tier II Canada Research Chair in Cardiovascular Medicine. Dr Eikelboom has published more than 170 articles in peer-reviewed journals. His current research, supported by the Canadian Institutes for Health Research, the Heart and Stroke Foundation and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies in arterial and venous thrombosis, the prognostic importance of bleeding and transfusion, and the mechanisms of variable response to antiplatelet drugs.

Ms Lisa Elliot, SA

Lisa Elliott is Clinical Service Coordinator of the Oncology Day Centre at the Royal Adelaide Hospital. Following her training at Modbury Hospital, she worked for 5 years in haematology/bone marrow transplant inpatient units at the Royal Adelaide Hospital and the Hammersmith Hospital in London, before moving into ambulatory care, where she has been for 19 years. Her current role encompasses provision of care for patients receiving chemotherapy and supportive treatments in the outpatient setting. She has a Graduate Diploma in Nursing Science (Oncology) and a Master of Nursing Science (Nurse Practitioner).

Dr Peter Flanagan, New Zealand

Peter Flanagan trained in haematology and transfusion medicine in the United Kingdom. He worked as a consultant in transfusion medicine for the National Blood Service for 10 years. He developed a special interest in blood safety and quality systems. In 1998 he moved to New Zealand to take up the position of National Medical Director in the newly created New Zealand Blood Service. He has played a key role in the development of a national blood service in New Zealand. He is on the editorial board of Vox Sanguinis, is President of the ANZSBT Council, member of the ISBT Council and also a member of a number of ISBT expert committees.

Australasian Speakers

Professor Robert Flower, QLD

Robert Flower is the Major Program Leader, Transfusion Science at the ARCBS a national role based in Brisbane. Professor Flower has over 30 years experience in teaching and research in transfusion science, virology and immunology. As MPL he aims to continue to provide a quality customer-focussed service while facilitating leading edge research in the ARCBS. Professor Flower has supervised completion of research projects by more than 30 research students and published over 130 refereed papers in scientific journals.

Dr Bernd Froessler, SA

Bernd Froessler is a Staff Specialist in Anaesthesia. Bernd was born in Germany and completed undergraduate and postgraduate training in Germany, working as a specialist in Germany, Holland and Australia. Bernd has a special interest in blood conservation, cardio-thoracic, obstetric anaesthesia and echocardiography. He has research interests in peri-operative anaemia management. Bernd is a member of National Blood Authority's Blood Measures Working Group and a member of a National Anaemia Management Advisory Committee.

Dr Harry Gibbs, QLD

Harry Gibbs is a graduate of the University of Sydney. He trained in Cardiology and Vascular Medicine at St. Vincent's Hospital, Sydney with subsequent training at The Cornell University Medical Center, New York. He is currently the Director of the Department of Vascular Medicine at the Princess Alexandra Hospital, Brisbane and an Associate Professor of Medicine at the University of Queensland. He is a member of the ANZ Working party on the Prevention of Venous Thromboembolism. His interests are in the non-invasive diagnosis and the management of disorders of the arterial, venous and lymphatic circulations.

Ms Lyn Green, SA

Lyn Green is Clinical Service Coordinator, Royal Adelaide Hospital, Central Northern Area Health Service. She has 20 years in experience in diabetes care and has a particular interest in the care of patients with diabetes in the acute sector.

Ms Wendy Harris, NSW

Wendy Harris is a multi-skilled Medical Scientist with 25 years laboratory experience in both private and public Pathology. She has held senior positions for many years and was a Laboratory Manager for stat laboratories for 13 years in both Queensland and New South Wales. Five years ago she took my laboratory experience to NATA Medical Testing and has been responsible for setting up the accreditation module for Apheresis and training their group of Apheresis assessors.

Dr Stewart Hay, VIC

Stewart Hay was appointed to the role of CEO of Research Infrastructure Support Services (RISS) in late 2008. He has a PhD, is a member of the Australian Institute of Project Management and has a diverse background in the science industry having worked in medical research and the pharmaceutical, nutraceutical and medical device industries. In his prior role he managed the implementation of a \$60 million research infrastructure project which saw development of 11 facilities around Australia.

Mr Damien Heathcote, VIC

Damien Heathcote is the Immunohaematology Development and Quality Manager for CSL Bioplasma IH, a position he has held for the past four years. In this role he is responsible for the development of new Immunohaematology products and also has oversight of audit compliance and product registration in domestic and international markets. Prior to this role Damien lectured at the University of Tasmania in Haematology and Blood Transfusion, and held positions such as Deputy Head of School and Course Coordinator for the Biomedical Science program. By training he is a Medical Scientist, and he is a Fellow in Haematology of the Australian Institute of Medical Scientists. During his four years with CSL one of his major research programs has been the development of protein antigens for red cells, in particular for antibody screening cells.

A/Professor Robert (Bob) Heddle, SA

Robert (Bob) Heddle is Head of Clinical Immunology IMVS/Royal Adelaide Hospital. He has held senior clinical posts as a Clinical Immunologist/Allergist at RAH, FMC, RGH and W&CH and until 2003 was also in private consultant rooms practice. He then took a position as Director of Allergy at FMC.



Haematology


Haematology - it's in our blood



Hospira is committed to supporting Australian haematology through the identification and in-licensing of novel compounds to complement our existing products. Our haematology portfolio includes agents that are being investigated to treat acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL). We are also interested in evaluating a range of new treatment options for other haematological conditions.

Hospira also supports local clinical trials, and professional and patient groups such as:

- the Australasian Leukaemia and Lymphoma Group (ALLG);
- the Haematology Society of Australia & New Zealand (HSANZ);
- the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG);
- the Bone Marrow Donor Institute (BMDI);
- the Leukaemia Foundation (LF);
- and the Red Kite Foundation.



Australasian Speakers

A/Professor Heddle's chief research interest has been in allergic disorders, especially stinging insect allergy and anaphylaxis. He has been active in professional associations including roles as President of ASCIA 1996-8, Specialty Advisory Board RACP 1996-2000, Hon Secretary Flinders Medical Staff Society 2005-8, member of Medical Advisory Committee FMC 2004-8, TSANZ Working Party on Omalizumab (2008) and ongoing roles as Convener of RCPA QAP in Allergy, Chairperson of SA IVIG Users' Group, Deputy Chairperson of ASCIA Anaphylaxis Working Party, Co-ordinator of Curriculum Development, Joint Specialist Advisory Committee RACP/RCPA in Clinical Immunology and Allergy and active roles in ASCIA Insect Allergy Working Party and MAC for Asthma SA. Other strong professional interests are clinical training and models for delivery of clinical care, especially in the context of demographic threats to continuity of manpower in Immunology/Allergy and appropriate use of IVIG and methods of delivery of the same.

Professor Steve Henry, New Zealand
Steve Henry, PhD, is the founder, CEO/CSO of KODE Biotech which is focused on cell surface modification/manipulation using KODE technology (<http://kodebiotech.com/?tech>). Steve also holds a professorial chair in Biotechnology at AUT University and leads the Biosurfaces Research Unit. Steve has published extensively in the scientific literature and is an inventor on numerous patent applications.

Dr Geoff Hill, QLD
Geoff Hill obtained his undergraduate and medical degree at the University of Auckland. His specialist Hematology training was undertaken in NZ, The Dana Farber Cancer Institute, and Harvard Medical School in Boston. Prof Hill is a NH&MRC Practitioner Fellow and is Head of Immunology with his own transplant immunology laboratory at the Queensland Institute of Medical Research. His focus is on the interactions between cytokines, antigen presenting cells and NKT / regulatory T cells during transplantation. His laboratory has published extensively in Blood, JCI and Nat Med on the topic and is funded by an ongoing NHMRC program. Dr Hill was named the 2005 "Queenslander of the year" and was the Transplantation Society of Australia and NZ 2009 Ian McKenzie Award recipient for his contribution to the transplant field over the last decade.

Professor Tim Hughes, SA
Timothy P. Hughes, MD, FRACP, FRCPA, is Head of the Department of Haematology at SA Pathology, RAH site, and Consultant Haematologist at the Royal Adelaide Hospital. He is also Clinical Professor of Medicine at the University of Adelaide and holds a Practitioner Fellowship from the National Health and Medical Research Council.

Mr Russell Hunt, SA
Russell Hunt is a Transfusion Nurse Consultant with the BloodSafe Program in the South Australia. After completing his training at the Royal Adelaide hospital he has worked at Flinders Medical Centre for the last 19 years with 10 years experience in the haematology oncology nursing. He joined Bloodsafe in September 2002. His current role incorporates BloodSafe and transfusion quality and safety activities at hospitals within the Southern Adelaide Health Service.

Ms Cheryl Hutchins
Ms Alison Keenan, SA
Alison Keenan is the Clinical Practice Consultant co-ordinating the Survivorship Programme at the Queen Elizabeth Hospital, Adelaide. This programme offers survivors of adult-onset blood malignancies a lifelong follow up to screen for any potential 'late effects' that their curative treatment may have caused. The programme began in May 2008 and encompasses the only clinic of its kind in South Australia.

Dr Andrew Lee, SA
Andrew Lee is a Stroke Physician and Neurologist at the Flinders Comprehensive Stroke Centre, Flinders University and medical Centre. He is a recipient of a NHMRC-NICS Fellowship 2008 2010 on increasing the efficiency of thrombolysis use. He received his medical training at the University of Adelaide and Neurology training at the Queen Elizabeth Hospital before taking up a Stroke Research Fellowship at Johns Hopkins Hospital, Baltimore Maryland and also completing a Masters of Public Health from Johns Hopkins University on the topic of Transient Ischemic Attack.

Dr Kevin Lynch, Celgene Pty Ltd, NSW

Dr Claire McClintock, New Zealand

Claire McLintock is a haematologist and obstetric physician at National Women's Health, Auckland City Hospital and was recently appointed as Clinical Director of Obstetric Medicine. Her main research interests are the placental mediated pregnancy problems such as preeclampsia, small for gestational age pregnancies, management of pregnancy in women with mechanical heart valves, venous thromboembolism in pregnancy and pregnancy complications in women with bleeding disorders. She is chair of the New Zealand Maternal Mortality Working Group and leader of the NZ branch of the Australasian Maternity Outcomes Surveillance Survey. Claire is on the council of ASTH and President of the Society of Obstetric Medicine of Australia and NZ.

Dr Simon McRae, SA

After undergoing undergraduate and physician training in Hobart, Tasmania, Dr McRae completed haematology training in Newcastle NSW. He then undertook a thrombosis clinical fellowship at McMaster University in Ontario Canada, returning to Adelaide SA at the start of 2006. Particular research interests include the use of laboratory tests to predict clinical outcome in patients with venous thrombosis and bleeding disorders, and evidence based management of patients with and at risk of venous thrombosis. Dr McRae co-ordinates a thrombosis clinical trial program at the Queen Elizabeth Hospital, and is also the Director of the Adult Haemophilia Treatment Centre based at the Royal Adelaide Hospital.

Professor Junia Melo, SA

Junia V. Melo graduated from the Faculty of Medicine, U.F.M.G. (Brazil) in 1974, did her Internal Medicine and Haematology training in Rio de Janeiro, Brazil, and earned her PhD from the Royal Postgraduate Medical School (RPMS), University of London in 1986. She did her first post-doctoral training in Adelaide, Australia, after which she was invited to re-join the RPMS as a team leader in the MRC/LRF Adult Leukaemia Unit in 1990. She established her research group at Imperial College London & Hammersmith Hospital from 1990 to 2007, as Professor of Molecular Haematology. In 2008 she took up the position of Head of Leukaemia Research at the Division of Haematology in the Hanson Institute,

IMVS, Adelaide. Her main research is focused on the molecular biology and cell kinetics of chronic myeloid leukaemia and related myeloproliferative disorders, and on identifying new molecular targets for the treatment of these diseases.

Ms Nancy Messino, VIC

Nancy Messino has worked in both diagnostic and research laboratory medical science in the areas of haematology, immunohaematology and Bone Marrow Transplantation. Currently she is the BMT FACT Project Coordinator for the HSCT Programme of the Children's Cancer Centre at the Royal Children's Hospital Melbourne, working towards FACT accreditation of the Collection, Processing and Clinical Facilities. Previously, she was Quality Manager of the Pathology Department and a Project Manager for the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre involved with both NATA and TGA accreditation processes. Other roles include Treasurer of the BMTSAA, chairperson of the VIDG, part-time academic at RMIT and NATA assessor.

Mrs Barbara Parker, SA

As a Transfusion Nurse Consultant with the SA BloodSafe Program, Barbara Parker undertakes activities aimed at improving the safety, quality and efficiency of blood and blood product usage at both The Queen Elizabeth and Lyell McEwin Hospitals. She has also been working with the Blood Organ and Tissue Programs Unit, Department of Health providing BloodSafe support/advice consultancy services. Barbara has a background in Haematology/Oncology nursing and since being part of BloodSafe has developed a keen interest in Patient Blood Management, particularly the management of iron deficiency anaemia. Funding has recently been provided by the Department of Health for a Statewide BloodSafe Program Extension Project – Iron Deficiency Anaemia and Patient Blood Management which Barbara will be involved in.

Dr Kurosh Parsi, NSW

Kurosh Parsi, FACD, FACP is a dermatologist, phlebologist and vascular anomalies specialist. Dr Parsi is a medical graduate of the University of Sydney and obtained his Master of Science in Medicine degree from the University of New South Wales (UNSW). Dr Parsi's research interests have

Australasian Speakers

included traveller's thrombosis, thrombophilia, thrombo-haemostatic and lytic effects of sclerosing agents, and pigmented purpuric dermatoses. Dr Parsi's clinical interests include endovenous laser therapy, ultrasound guided sclerotherapy, management of vascular malformations, and thromboembolic disorders. He is the founding editor of the Australian and New Zealand Journal of Phlebology. Dr Parsi is the current Associate Editor of the Australasian Journal of Dermatology and serves on the Editorial Board of Phlebology: The Journal of Venous Disease.

Dr Natalie Pecheniuk, QLD

Natalie Pecheniuk is a lecturer in Biochemistry and Molecular Biology at James Cook University, Queensland. Natalie obtained her PhD from Queensland University of Technology in 2001 prior to postdoctoral and staff scientist positions at The Scripps Research Institute, La Jolla, California, under the mentorship of Professor John Griffin. Her major research interests include the molecular role of lipids and lipoproteins in procoagulant and anticoagulant pathways, in addition to identifying novel biochemical and genetic risk factors associated with venous thrombosis.

Professor John Rasko, NSW

John Rasko is a haematologist who directs Cell and Molecular Therapies at Royal Prince Alfred Hospital and heads the Gene and Stem Cell Therapy Program at the Centenary Institute, University of Sydney. His was the first formal appointment in clinical gene therapy in Australia. He is a past President of the Australasian Gene Therapy Society and Vice President of the International Society for Cellular Therapy.

A/Professor Tamas Revesz, SA

Tamas Revesz worked in The Netherlands before joining the Women's & Children's Hospital as head of the Haematology-Oncology team in 2004. He has a long-standing interest in the biology and treatment of childhood leukaemia and has published extensively on the subject. His other major contributions are in the area of bone marrow transplantation. He is currently the Australia-New Zealand coordinator of the R3 international study on childhood relapsed acute lymphoblastic leukaemia.

Dr Andrew Roberts, VIC

Andrew Roberts is a clinical haematologist at the Royal Melbourne Hospital as well as an NHMRC Practitioner Fellow and Head of Clinical Translation at the Walter & Eliza Hall Institute. His current major research interests are understanding the molecular regulation of haemopoiesis and the development of new treatments for lymphoma and leukaemia through translational and clinical research. He was President of HSAZ 2005–07, and since 2007 has been an appointed member of the Pharmaceutical Benefits Advisory Committee to the Australian Government.

Dr Kathryn Robinson, SA

Kathryn Robinson is a haematologist and transfusion medicine specialist at the Australian Red Cross Blood Service and the Queen Elizabeth Hospital in Adelaide, South Australia. She holds a joint fellowship with the Royal Australian College of Physicians and Pathologists, training in Adelaide, Melbourne and Oxford. Kathryn is the clinical lead of "BloodSafe", a state-wide collaborative program to improve the safety and appropriateness of clinical transfusion practice. She has a particular interest in anaemia management and iron deficiency. In May 2009 Kathryn helped to coordinate a national meeting bringing together a multi-professional group of experts with a common interest in improving the management of iron deficiency anaemia.

M. Taher Shabani-Rad (Taher Rad), Canada

Shabani-Rad is director of the Transfusion Medicine and assistant professor of pathology at the University of Calgary/Calgary Laboratory services, Alberta, Canada. He is also consultant haematopathologist for TBCC (Tom Baker Cancer Centre) and member of South Alberta Lymphoma Pathology Group. He has completed a fellowship in haematopathology and transfusion medicine at the UCLA-Medical Center, LA, California (2006-7). Since July 2007 he has been working at the division of haematopathology and transfusion medicine at Foothills medical Centre. Dr Rad is a fellow of RCPSC (Royal College of Physicians and Surgeons of Canada) and CAP and also serves as member of NAC (National advisory committee for blood and blood products) as well as National Committee for Blood Shortage and Contingency Plans of Canada.

Professor Andrew Spencer, VIC

Andrew Spencer is presently Principal Specialist and Head of the Malignant Haematology & Stem Cell Transplantation Service at The Alfred Hospital, Melbourne; an Associate Professor in the Department of Clinical Haematology, Central Clinical School, Monash University; and, Head of the Myeloma Research Group at the Australian Centre for Blood Diseases, Melbourne. He is actively involved in both translational and early phase clinical research with a particular interest in microenvironmental mechanisms of drug resistance and the development of novel pharmacological and transplant approaches for the treatment of multiple myeloma and related haematological malignancies. He is a member of the Medical Advisory Group for the Australian Myeloma Foundation and serves on the Scientific Advisory Boards of the International Myeloma Foundation (IMF), the International Myeloma Working Group (IMWG) and the European Myeloma Network (EMN).

Ms Judith Stevens, SA

Judy Stevens commenced working in the Therapeutic Products Facility at SA Pathology Royal Adelaide in 1995, as a processing technician. She is currently the Production Manager: Progenitor Cell and Blood and Tissue in the Therapeutic Products Facility, with responsibility for the efficient operation of these units. Prior to this, she worked worked in the Haemostasis Section at SA Pathology, and the Emergency Laboratory at SA Pathology, commencing my career in 1984.

Professor Jeff Szer, VIC

Jeff Szer is Director of the Department of Clinical Haematology at Royal Melbourne Hospital. He sits on committees of a number of national and international BMT groups and is the current president of the BMTSANZ. His clinical research interests are in all aspects of malignant and life-threatening non-malignant haematological diseases.

Dr Huyen Tran, VIC

Huyen Tran is a consultant haematologist and is currently Acting Head of Clinical Haematology Unit at Monash Medical Centre, and Acting Director of Haemophilia Treatment Centre and Thrombosis Services at The Alfred Hospital.

VELCADE® expands the possibilities.

For your patients with multiple myeloma

VELCADE
(bortezomib)

PBS Information: Authority required. Refer to PBS Schedule for full authority information.

JANSSEN-CILAG

Please review approved Product Information before prescribing. Full Product Information is available on request. Janssen-Cilag Pty Ltd, ABN 47 000 129 975, 1-5 Kharatoum Road, North Ryde NSW 2113. VELCADE® is the registered trademark of Millennium Pharmaceuticals for bortezomib injection.

Medtel
Blood Processing

Therakos HAEMONETICS® biosafe

Providing Your Blood Management Solutions

MTBL10NAU0809

HAEMONETICS MCS+ • PCS2 • TEG 5000 • CellSaver 5+ • OrthoPAT
BIOSAFE Sepax • THERAKOS CelliEX

FOR MORE INFO VISIT MEDTEL STAND#60
5 Orion Road, Lane Cove, NSW 2066
Australia : 1300 886 385 NZ : 0800 733 333
info@medtel.com.au www.medtel.com.au

Australasian Speakers

Dr Annette Trickett, NSW

Annette Trickett has worked in the field of blood and marrow transplantation for 24 years, during which time she has completed MSc and PhD theses in cellular therapy, established and run a BMT laboratory, directed public Cord Blood Banks in Sydney and Melbourne, and is now Quality Manager of the BMT Network NSW. Facilities under her direction have attained NATA accreditation, TGA licensure and FACT accreditation.

Dr Alison Turner, ACT

Alison Turner was appointed as CEO and General Manager of the National Blood Authority in August 2003 and reappointed in 2007. The National Blood Authority is an Australian Government statutory agency, established to improve and enhance the management of the Australian blood and plasma product sector at a national level. As CEO and General Manager, Dr Turner frequently speaks nationally on issues pertinent to the blood sector and has represented Australia internationally in which she represents the key goals of the National Blood Authority. Prior to joining the NBA, Dr Turner was Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority as well as holding a number of senior government executive positions in the health and primary industries' sectors.

Ms Beverley Wake, SA

Beverley Wake worked in the haematology and oncology inpatient and day patient areas of the Royal Adelaide Hospital in the 1980s. In the 1990s she was employed by the Institute of Medical and Veterinary Science as a Clinical Nurse providing apheresis services to the Royal Adelaide Hospital as well as a day patient service for haematology/ oncology and neurology patients. Currently she is the acting Clinical Services Coordinator of the Haematology Day Centre at the Royal Adelaide Hospital. She has a Graduate Certificate in Nursing Science (Apheresis).

A/Professor Chris Ward, NSW

Chris Ward is a Clinical Haematologist in the Department of Haematology and Transfusion Medicine, Royal North Shore Hospital with research interests in coagulation, myeloma and vascular biology. He is the Director of the Northern Blood Research Centre, supervising research in platelet function, hypercoagulability in cancer and other disease states, and global tests of coagulation. The Centre maintains a busy clinical trials programme and A/Professor Ward is the lead investigator for coagulation trials. He is the current President of the Australasian Society for Thrombosis and Haemostasis.

Ms Rachel Whitford, SA Department of Health, SA

Dr Erica Wood, VIC

Erica Wood manages the national Transfusion Medicine Services team at the Australian Red Cross Blood Service (ARCBS). She holds a consultant haematologist position at Bayside Health, and honorary consultant haematologist positions at The Royal Melbourne Hospital and Peter MacCallum Cancer Centre. Erica is a member of the advisory committee of Blood Matters and the chair of the Serious Transfusion Incident Reporting (STIR) haemovigilance programme. She serves on ANZSBT Council and has participated in its Clinical Practice Improvement Committee (2007-2009) and Scientific Subcommittee (2005-07). Her interests include clinical transfusion research, and she is actively involved in teaching, currently serving as Associate Chief Examiner in Haematology for the RCPA and on the RACP/RCPA Haematology JSAC. Erica is a member of the ISBT working parties on haemovigilance and transfusion-transmissible diseases and has served as a WHO regional advisor in blood safety.

A/Professor Andrew Zannettino, SA

Andrew Zannettino is a Chief Medical Scientist, SA Pathology, and Associate Professor of Medicine, University of Adelaide. His research efforts focus on the mechanisms of skeletal disease in myeloma. He has co-authored more than 90 publications, book chapters, review articles and patents and is a founding member of the Medical and Scientific Advisory Group of the Myeloma Foundation of Australia Inc.